WO2011088215A3 - Notch1 binding agents and methods of use thereof - Google Patents

Notch1 binding agents and methods of use thereof Download PDF

Info

Publication number
WO2011088215A3
WO2011088215A3 PCT/US2011/021135 US2011021135W WO2011088215A3 WO 2011088215 A3 WO2011088215 A3 WO 2011088215A3 US 2011021135 W US2011021135 W US 2011021135W WO 2011088215 A3 WO2011088215 A3 WO 2011088215A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
present
notch1
agents
treating
Prior art date
Application number
PCT/US2011/021135
Other languages
French (fr)
Other versions
WO2011088215A2 (en
Inventor
Edward Thein Htun Van Der Horst
Original Assignee
Oncomed Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharmaceuticals, Inc. filed Critical Oncomed Pharmaceuticals, Inc.
Priority to CN201180009457.3A priority Critical patent/CN102958534B/en
Priority to EP11733378.1A priority patent/EP2523682B1/en
Priority to AU2011205316A priority patent/AU2011205316B2/en
Priority to ES11733378.1T priority patent/ES2561102T3/en
Priority to MX2012008085A priority patent/MX2012008085A/en
Publication of WO2011088215A2 publication Critical patent/WO2011088215A2/en
Publication of WO2011088215A3 publication Critical patent/WO2011088215A3/en
Priority to HK13108710.7A priority patent/HK1181316A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.
PCT/US2011/021135 2010-01-13 2011-01-13 Notch1 binding agents and methods of use thereof WO2011088215A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN201180009457.3A CN102958534B (en) 2010-01-13 2011-01-13 Notch1 binding agents and methods of use thereof
EP11733378.1A EP2523682B1 (en) 2010-01-13 2011-01-13 Notch1 binding agents and methods of use thereof
AU2011205316A AU2011205316B2 (en) 2010-01-13 2011-01-13 Notch1 binding agents and methods of use thereof
ES11733378.1T ES2561102T3 (en) 2010-01-13 2011-01-13 Binding agents to Notch1 and procedures for their use
MX2012008085A MX2012008085A (en) 2010-01-13 2011-01-13 Notch1 binding agents and methods of use thereof.
HK13108710.7A HK1181316A1 (en) 2010-01-13 2013-07-25 Notch1 binding agents and methods of use thereof notch1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29476210P 2010-01-13 2010-01-13
US61/294,762 2010-01-13
US41065110P 2010-11-05 2010-11-05
US61/410,651 2010-11-05

Publications (2)

Publication Number Publication Date
WO2011088215A2 WO2011088215A2 (en) 2011-07-21
WO2011088215A3 true WO2011088215A3 (en) 2011-09-29

Family

ID=44304970

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/021135 WO2011088215A2 (en) 2010-01-13 2011-01-13 Notch1 binding agents and methods of use thereof

Country Status (8)

Country Link
US (1) US8834875B2 (en)
EP (1) EP2523682B1 (en)
CN (1) CN102958534B (en)
AU (1) AU2011205316B2 (en)
ES (1) ES2561102T3 (en)
HK (1) HK1181316A1 (en)
MX (1) MX2012008085A (en)
WO (1) WO2011088215A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2032166T3 (en) 2006-06-13 2013-09-30 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
JP5618544B2 (en) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosis and treatment of cancer
AU2009269095B2 (en) 2008-07-08 2016-05-19 Oncomed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2010146550A1 (en) 2009-06-18 2010-12-23 Pfizer Inc. Anti notch-1 antibodies
RU2622083C2 (en) 2010-12-15 2017-06-09 ВАЙЕТ ЭлЭлСи Anti-notch1 antibodies
WO2012080891A1 (en) * 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies
WO2013119923A1 (en) 2012-02-09 2013-08-15 The Regents Of The University Of Michigan Different states of cancer stem cells
CA2885659A1 (en) * 2012-09-21 2014-03-27 Oncomed Pharmaceuticals, Inc. Methods of treating hematological malignancies with notch1 antibodies
US20160237152A1 (en) * 2012-12-21 2016-08-18 The Regents Of The University Of California Tspan 33 is a candidate for antibody targeted therapy for the treatment of b cell hodgkin lymphomas
WO2014172653A2 (en) * 2013-04-19 2014-10-23 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
CN103820498B (en) * 2014-01-29 2016-08-17 中国人民解放军第四军医大学 A kind of Lentiviral built based on Notch signal intracellular territory NICD1 and application thereof
BR112017000130A2 (en) 2014-07-11 2018-01-09 Genentech Inc method for mitigating toxicity associated with notch pathway inhibition and cancer treatment method
MX2017005258A (en) * 2014-10-31 2017-07-26 Oncomed Pharm Inc Combination therapy for treatment of disease.
CN105585636B (en) * 2015-11-24 2020-03-03 南方医科大学 Human NOTCH1NICD protein Ser2162 site phosphorylation antibody and preparation method and application thereof
CN106591229A (en) * 2017-01-20 2017-04-26 南京千年健干细胞基因工程有限公司 Application of miR-34a and target gene NOTCH1 to preparation of mesenchymal stem cell based glioma targeting carrier
EP3710048A4 (en) * 2017-11-17 2021-08-18 University of Massachusetts Humanized 2c7 monoclonal antibody directed against aneisseria gonorrhoeae
WO2020097155A1 (en) * 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080588A (en) * 1995-05-18 2000-06-27 The Regents Of The University Of Michigan Therapeutic methods for benzodiazepine derivatives
US20040229301A1 (en) * 2003-04-22 2004-11-18 Baiyang Wang Tissue factor antibodies and uses thereof
US20050142635A1 (en) * 1991-04-25 2005-06-30 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6 receptor
US20090028856A1 (en) * 2007-07-16 2009-01-29 Genentech, Inc. Anti-CD79B Antibodies and Immunoconjugates and Methods of Use
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
US7632926B2 (en) * 2006-04-01 2009-12-15 Galaxy Biotech, Llc Humanized monoclonal antibodies to hepatocyte growth factor

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
DE69233745D1 (en) 1991-12-02 2008-10-23 Cambridge Antibody Tech Preparation of Autoantibodies on Phage Surfaces Starting from Antibody Segment Libraries
US20050112121A1 (en) 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
DE4425115A1 (en) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Method for modifying the stability of antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
DK0859841T3 (en) 1995-08-18 2002-09-09 Morphosys Ag Protein / (poly) peptide libraries
ES2177964T3 (en) 1996-03-30 2002-12-16 Science Park Raf S P A PROCEDURE OF PRODUCTION OF ACTIVATED T CELLS MARKED SPECIFIC TUMORS AND ITS USE FOR TUMOR TREATMENT.
CA2256481A1 (en) 1996-05-31 1997-12-04 The National American Red Cross Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
FR2751986B1 (en) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med GENE INVOLVED IN CADASIL, DIAGNOSTIC METHOD AND THERAPEUTIC APPLICATION
US6379925B1 (en) 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
WO1998057621A1 (en) 1997-06-18 1998-12-23 The Trustees Of Columbia University In The City Ofnew York Angiogenic modulation by notch signal transduction
US6692919B1 (en) 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
EP1117778A2 (en) 1998-10-02 2001-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein
DE69933576T2 (en) 1998-11-05 2007-06-21 Japan Science And Technology Agency, Kawaguchi ADULT MODELS FOR T-CELL LEUKEMIA
US20030003572A1 (en) 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
ATE482275T1 (en) 1999-07-02 2010-10-15 Morphosys Ag GENERATION OF SPECIFIC BINDING PARTNERS THAT BIND TO (POLY)PEPTIDES ENCODED BY GENOMIC DNA FRAGMENTS OR ESTS
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
DE10031380A1 (en) 2000-06-28 2002-01-10 Merck Patent Gmbh Process for the transfer of alkylidene groups to organic compounds
US20050089518A1 (en) 2001-12-07 2005-04-28 Clarke Michael F. Prospective identification and characterization of breast cancer stem cells
US20080194022A1 (en) 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6930222B2 (en) 2000-08-22 2005-08-16 The Scripps Research Institute In vivo animal model of human leukemia
AU2001288628A1 (en) 2000-08-31 2002-03-13 Loyola University Chicago Method and reagents for treatment of skin disorders by modulating the notch pathway
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
PT1355919E (en) 2000-12-12 2011-03-02 Medimmune Llc Molecules with extended half-lives, compositions and uses thereof
US7356224B2 (en) 2001-07-03 2008-04-08 Brown University Research Foundation Method and apparatus for detecting multiple optical wave lengths
JP2005526701A (en) 2001-11-14 2005-09-08 ロランティス リミテッド Internal medicine
GB0201674D0 (en) 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
US20060275287A1 (en) 2002-06-21 2006-12-07 Brad St Croix Scroll compressor
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003284357A1 (en) 2002-11-01 2004-06-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR20050094400A (en) 2002-12-06 2005-09-27 싱가포르 제너럴 하스피털 피티이 엘티디. Nogo, caspr, f3, nb-3 useful in the treatment of injury and disease to the central nervous system
EP1608255A4 (en) 2003-04-01 2008-06-25 Univ Johns Hopkins Med Breast endothelial cell expression patterns
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
JP2007512348A (en) 2003-11-26 2007-05-17 ヘルス　リサーチ　インコーポレイテッド Use of Notch pathway interference agents for the treatment of plasma cells
CA2554779A1 (en) 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
EP1730531B1 (en) 2004-03-24 2014-01-15 Technion Research and Development Foundation, Limited Electrode
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
WO2006024497A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
GB0421838D0 (en) 2004-09-30 2004-11-03 Congenia S R L Cancer markers
EP1824503A1 (en) 2004-11-10 2007-08-29 Hubrecht Laboratorium Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
WO2006051405A2 (en) 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
JP2008535494A (en) 2005-04-07 2008-09-04 サグレシュ ディスカバリー， インコーポレイテッド Cancer-related gene (PRLR)
EP1945754B1 (en) 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP5489465B2 (en) 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Method of treating tumor growth inhibition with a Dll4 antagonist
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
AR061245A1 (en) 2006-06-06 2008-08-13 Genentech Inc COMPOSITIONS AND METHODS FOR VASCULAR DEVELOPMENT MODULATION
JP2009539384A (en) 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド Anti-DLL4 antibody and method of using anti-DLL4 antibody
PL2032166T3 (en) 2006-06-13 2013-09-30 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Compositions and methods for diagnosing and treating cancer
KR101525629B1 (en) 2006-10-19 2015-06-26 제넨테크, 인크. Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
WO2008136848A2 (en) 2006-10-19 2008-11-13 Genentech Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2008048680A2 (en) 2006-10-19 2008-04-24 Maine Medical Center Research Institute Notch 2 signaling as a breast cancer suppressor pathway
RU2448979C2 (en) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Human antibodies to delta-like human ligand-4
RU2493167C2 (en) 2006-12-18 2013-09-20 Дженентек, Инк. ANTIBODIES-ANTAGONISTS AGAINST Notch3 AND THEIR APPLICATION FOR PREVENTION AND TREATMENT OF Notch3-RELATED DISEASES
EP2120996A2 (en) 2006-12-20 2009-11-25 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
JP5618544B2 (en) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosis and treatment of cancer
JP2010517944A (en) 2007-01-26 2010-05-27 バイオインヴェント インターナショナル アーベー DLL4 signaling inhibitor and use thereof
WO2008108910A2 (en) 2007-03-05 2008-09-12 Board Of Regents, The University Of Texas System Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy
PE20090321A1 (en) * 2007-06-04 2009-04-20 Genentech Inc ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION
KR20100076947A (en) 2007-08-23 2010-07-06 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 Compositions of humanized notch fusion proteins and methods of treatment
US8377886B2 (en) 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
EP2275431A3 (en) 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
AU2009269095B2 (en) 2008-07-08 2016-05-19 Oncomed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142635A1 (en) * 1991-04-25 2005-06-30 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6 receptor
US6080588A (en) * 1995-05-18 2000-06-27 The Regents Of The University Of Michigan Therapeutic methods for benzodiazepine derivatives
US20040229301A1 (en) * 2003-04-22 2004-11-18 Baiyang Wang Tissue factor antibodies and uses thereof
US7632926B2 (en) * 2006-04-01 2009-12-15 Galaxy Biotech, Llc Humanized monoclonal antibodies to hepatocyte growth factor
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
US20090028856A1 (en) * 2007-07-16 2009-01-29 Genentech, Inc. Anti-CD79B Antibodies and Immunoconjugates and Methods of Use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE SWISS-PROT [online] 31 October 2006 (2006-10-31), "Anti-MOG Z12 variable gamma 2a.", retrieved from http://www.ncbi.nlm.nih.gov/protein/Q8VDC9 Database accession no. 08VDC9 *
DATABASE SWISS-PROT [online] 4 November 2008 (2008-11-04), "Ig lambda-1 chain V regions MOPC 104E/RPC20/J558/S104.", retrieved from http://www.ncbi.nlm.nih.gov/proteiN126540?sat=OL106&satkey=9150932 Database accession no. P01724. *
See also references of EP2523682A4 *

Also Published As

Publication number Publication date
CN102958534A (en) 2013-03-06
ES2561102T3 (en) 2016-02-24
EP2523682A2 (en) 2012-11-21
EP2523682B1 (en) 2015-12-16
US20120213786A1 (en) 2012-08-23
AU2011205316A1 (en) 2012-08-02
WO2011088215A2 (en) 2011-07-21
CN102958534B (en) 2014-11-05
HK1181316A1 (en) 2013-11-08
AU2011205316B2 (en) 2015-05-28
US8834875B2 (en) 2014-09-16
EP2523682A4 (en) 2013-05-29
MX2012008085A (en) 2012-09-12

Similar Documents

Publication Publication Date Title
WO2011088215A3 (en) Notch1 binding agents and methods of use thereof
MY155603A (en) Notch-binding agents and antagonists and methods of use thereof
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
WO2014012007A3 (en) Rspo3 binding agents and uses thereof
MX2018010331A (en) Vegf/dll4 binding agents and uses thereof.
MX349198B (en) Rspo binding agents and uses thereof.
WO2011063237A3 (en) Jagged-binding agents and uses thereof
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
WO2011119979A3 (en) Antibodies to muc16 and methods of use thereof
WO2009142738A3 (en) Compositions and methods for diagnosing and treating cancer
EP2582722A4 (en) Anti-gd2 antibodies
EA033400B1 (en) Anti-cd3 antibody and use thereof
WO2013071068A3 (en) Treatment of hematologic malignancies with an anti-cxcr4 antibody
MX2009013656A (en) Anti-cd20 therapeutic compositions and methods.
UA94452C2 (en) Humanized monoclonal antibodies to hepatocyte growth factor
EP2175879A4 (en) Treatment of prion protein related diseases
PH12020551447A1 (en) Antibodies
WO2008142303A3 (en) Use of an anti-cxcr4 antibody for treating cancer
MX2009003039A (en) Use of an anti-cd151 antibody in the treatment of cancer.
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
WO2008070090A3 (en) Compositions and methods for diagnosing and treating cancer
WO2010066914A3 (en) Remedies for pemphigus containing anti fas ligand antibodies
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
WO2007007152A3 (en) Anti-madcam antibodies to treat metastatic cancers and chloroma

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180009457.3

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2011205316

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/008085

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011733378

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011205316

Country of ref document: AU

Date of ref document: 20110113

Kind code of ref document: A